Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay
|
|
- Frederick Henry
- 6 years ago
- Views:
Transcription
1 pplication Note Immunotherapy Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RN in situ hybridization RNscope assay Ming-Xiao He, Na Li, Courtney nderson, Yuling Luo, Nan u, Xiao-Jun Ma, Emily Park he RNscope assay is a unique RN IH technology that identifies RN expression at the single cell level with morphological context. Here we present the use of RNscope for the detection of RN targets in the tumor microenvironment (ME) that are involved in tumor immunology and immunotherapy: Checkpoint markers Immune cell markers Cytokines and chemokines Detection of these RN targets with the RNscope assay can aid in: Localization of specific immune cell types (i.e., cytotoxic lymphocytes and regulatory cells) in the ME Determining spatial relationships between different cell types in the ME Characterization of secreted proteins (i.e., cytokines and chemokines) Evaluation of immune function in ME beyond enumeration of tumor infiltrating lymphocytes Introduction he field of cancer immunotherapy has expanded rapidly in recent years with immune checkpoint inhibitors and other therapeutic approaches such as cancer vaccines and chimeric antigen receptor (CR) therapy showing promising clinical results. Despite the dramatic and durable responses seen in many patients, our understanding of the immune response to cancer is still limited, and we cannot reliably predict who will or will not benefit from these new interventions. o better stratify patients for immunotherapy treatments, the series of events and biomarkers involved in the cancer immunity cycle need to be better understood (1-3). In addition, spatially mapped expression data at the single-cell level is crucial to understanding the cellular organization and cell-to-cell interactions in the tumor and its complex microenvironment (ME). RNscope is a unique RN IH technology that provides single-cell gene expression resolution with spatial and morphological context. he RNscope assay detects mrn and long noncoding RNs in fresh frozen, fresh fixed, and formalin-fixed paraffin-embedded (FFPE) cells and tissues by utilizing a unique double Z probe design and signal amplification strategy that allows for visualization of target RN as a single dot, where each dot is an individual RN molecule (4). he RNscope strategy offers the key benefits of high sensitivity due to the signal amplification method, and high specificity because of the double Z probe design, resulting in a high signal-to-noise ratio in many tissues. In this report we examined 50 selected immune checkpoint and functional markers (summarized in Figure 1) to demonstrate the utility of the RNscope assay for tumor immunology applications. With the RNscope 2.5 HD duplex assay we demonstrate localization of PD-L1 and several immune markers in ovarian and lung cancers (Figures 2-4). Detection of 12 immune checkpoint markers, 14 immune cell markers, and 24 immune function markers, such as cytokines and chemokines, in multiple human tumors is also demonstrated by the RNscope brown assay (Figures 5-7; ppendix). he complete data set can be viewed in the appendix available online at 1
2 Checkpoint markers Immune cell markers Cytokines and chemokines L (CD272) CD3 CCL5 IL10 CL4 CD8α (CD8) CCL7 IL12 IDO1 CD27 CX3CL1 IL13 IM3 (HVCR2) CD40 CX3CR1 IL17 LG3 CD40L (CD40LG) CXCL9 IL18 MIC CD70 CXCL10 IL20 MIC FOXP3 CXCL13 IL21 PD-1 (PDCD1) Granulysin (GNLY) IFN1 IL33 PD-L1 (CD274) ICM1 IFNγ (IFNG) GFβ (GF1) PD-L2 (PDCD1LG2) ICO IL1 NFα (NF) 4-1/CD137 (NFRF9) Perforin (PRF1) IL4 VEGF- (VEGF) 7-H4 (VCN1) OX40L (NFF4) IL6 OX40 (NFRF4) IL7 HVEM (NFRF14) FIGURE 1. Immune markers examined in this study by the RNscope assay. Fifty immune system markers were examined in this study, including 12 immune checkpoint markers, 14 immune cell markers, and 24 cytokines and chemokines. Ovarian cancer Lung cancer PD-L1/CD8α FIGURE 2. imultaneous detection of PD-L1 and CD8α mrns. he manual RNscope 2.5 HD Duplex assay was used to detect expression of the immune checkpoint marker PD-L1 (green chromogen) and the immune cell marker CD8α (red chromogen) in human ovarian () and lung () tumors. Inset shows enlarged region outlined in white. sterisk denotes PD-L1+/CD8- cells; arrowhead denotes PD-L1+/CD8+ cells. Note that in the lung cancer sample () PD-L1 is profusely expressed in both tumor cells and immune cells, with abundant CD8+ immune cell infiltration. However, in the ovarian cancer sample () PD-L1 expression is primarily restricted to the immune cells., stroma;, tumor. White line delineates tumor margin. 40x magnification. 2 pplication Note
3 Ovarian cancer Lung cancer CD3/IFNγ D CD8α/IFNγ C F CD4/IFNγ E FIGURE 3. imultaneous detection of IFNγ and immune cell markers CD3, CD8α and CD4 mrns. he manual RNscope 2.5 HD Duplex assay was used to detect expression of the immune function marker IFNγ and the immune cell markers CD3 (-), CD8α (C-D), or CD4 (E-F) in human ovarian (, C, E) and lung (, D, F) tumors. CD3, CD8α, and CD4 were detected using green chromogen and IFNγ was detected using red chromogen. Inset shows enlarged region outlined in white. sterisk denotes CD+/IFNγ- cells; arrowhead denotes CD+/IFNγ+ cells; arrow denotes CD-/IFNγ+ cells., stroma;, tumor. White line delineates tumor margin. 40x magnification. Ovarian cancer Lung cancer CD4/FOXP3 FIGURE 4. imultaneous detection of FOXP3 and CD4 mrns. he manual RNscope 2.5 HD Duplex assay was used to detect expression of the immune cell markers CD4 (green chromogen) and FOXP3 (red chromogen) in human ovarian () and lung () tumors. Inset shows enlarged region outlined in white. sterisk denotes CD4+/FOXP3- cells; arrowhead denotes CD4+/FOXP3+ regulatory cells., stroma;, tumor. White line delineates tumor margin. 40x magnification. Immunotherapy 3
4 7-H4 ovary L testicle D CL4 lung IDO1 esophagus C F MIC ovary MIC ovary E H PD-1 ovary PD-L1 ovary G FIGURE 5. Detection of immune checkpoint markers in human tumors. he RNscope manual brown assay was used to detect expression of several immune checkpoint markers in multiple human tumors. 40x magnification. 4 pplication Note
5 CD3 ovary CD8α breast D HVEM gastric FOXP3 stomach C F ICM1 lung ICO stomach E H Perforin stomach OX40L liver G FIGURE 6. Detection of immune cell markers in human tumors. he RNscope manual brown assay was used to detect expression of several immune cell markers in multiple human tumors. 40x magnification. Immunotherapy 5
6 CXCL9 stomach CCL5 esophagus D CX3CR1 liver CXCL13 stomach C F IFNγ vulva IL1 bladder E H IL6 bladder IL33 normal stomach G J NFα breast GF1 stomach I FIGURE 7. Detection of cytokines, chemokines, and their receptors in human tumors. he RNscope manual brown assay was used to detect expression of several cytokines, chemokines, and their receptors in multiple human tumors. 40x magnification. 6 pplication Note
7 Conclusions Detecting RN biomarker expression at the single-cell level while preserving spatial information is critical to understanding cellular organization and cell-to-cell interactions in the cancer-immunity cycle. Here we show that the RNscope assay is able to detect immune checkpoint markers and immune function markers in a variety of human tumors. Overall these results demonstrate the utility of the RNscope technology in studying tumor immunology and key targets of immunotherapy in the tumor and its complex microenvironment. ppendix containing all data discussed in this study is available at acdbio.com/immunotherapy Markers Probe name Cat No. Checkpoint markers 7-H4 (VCN1) Hs-VCN L (CD272) Hs-L CD137/4-1 (NFRF9) Hs-NFRF CL4 Hs-CL IDO1 Hs-IDO IM3 (HVCR2) Hs-HVCR LG3 Hs-LG MIC Hs-MIC MIC Hs-MIC PD-1 (PDCD1) Hs-PDCD PD-L1 (CD274) Hs-CD PD-L2 (PDCD1LG2) Hs-PDCD1LG Immune cell markers CD3 Hs-CD3-pool CD8α (CD8) Hs-CD CD27 Hs-CD CD40 Hs-CD CD40L (CD40LG) Hs-CD40LG CD70 Hs-CD FOXP3 Hs-FOXP Granulysin (GNLY) Hs-GNLY HVEM (NFRF14) Hs-NFRF ICM1 Hs-ICM ICO Hs-ICO Markers Probe name Cat No. Cytokines and chemokines CCL5 Hs-CCL CCL7 Hs-CCL CX3CL1 Hs-CX3CL CX3CR1 Hs-CX3CR CXCL9 Hs-CXCL CXCL10 Hs-CXCL CXCL13 Hs-CXCL IFN1 Hs-IFN IFN-γ (IFNG) Hs-IFNG IL1 Hs-IL IL4 Hs-IL IL6 Hs-IL IL7 Hs-IL IL10 Hs-IL IL12 Hs-IL IL13 Hs-IL IL17 Hs-IL IL18 Hs-IL IL20 Hs-IL IL21 Hs-IL IL33 Hs-IL GF-β (GF1) Hs-GF NF-α (NF) Hs-NF VEGF- (VEGF) Hs-VEGF OX40L (NFF4) Hs-NFF OX40 (NFRF4) Hs-NFRF Perforin (PRF1) Hs-PRF Immunotherapy 7
8 Probes for duplex assay Markers Probe name Cat # PD-L1/CD8 Hs-CD Hs-CD8-C C2 PD-L1/CD3 Hs-CD Hs-CD3-pool-C C2 CD3/IFNG Hs-CD3-pool Hs-IFNG-C C2 CD8a/IFNG Hs-CD Hs-IFNG-C C2 References 1. Pardoll DM. he blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4): Chen D and Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1): umeh PC et al. PD-1 blockade induces new responses by inhibiting adaptive immune response. Nature. 2014; 515(7528): Wang F, Flanagan J, u N, Wang LC, ui, Nielson, Wu X, Vo H, Ma XJ, Luo Y. RNscope: novel in situ RN analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012; 14(1):22-9. DICLIMER ll samples used in this study have been qualified for RN integrity with PPI and dap control probes before target probe analysis. lways qualify your samples as describe in the getting started section You may observe a difference in staining pattern, due to variation in tissue preparation methods or associated biology within the tissue samples. CD4/IFNG Hs-CD Hs-IFNG-C C2 CD4/FOXP3 Hs-CD Hs-FOXP3-C C2 Data not included in this report. o read additional pplication Notes, visit For Research Use Only. Not for diagnostic use. RNscope is a registered trademark of dvanced Cell Diagnostics, Inc. in the United tates or other countries. ll rights reserved dvanced Cell Diagnostics, Inc. Doc #: /Rev/Effective Date03/31/2016 California, U
International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
More informationA fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue
A fresh approach to Immuno-oncology: Ex vivo analysis of drug efficacy in fresh patient tumortissue Soner Altiok, MD, PhD Chief Scientific Officer Nilogen Oncosystems Tampa, Florida - Nilogen Oncosystems,
More informationTumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationSupplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs
Supplementary Table Clinicopathological characteristics of 35 patients with CRCs Characteristics Type-A CRC Type-B CRC P value Sex Male / Female 9 / / 8.5 Age (years) Median (range) 6. (9 86) 6.5 (9 76).95
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics
ACE ImmunoID Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. ACE ImmunoID When one biomarker doesn t tell the whole
More informationMelanoma gene expression profiles to identify mechanisms of tumor resistance
Melanoma gene expression profiles to identify mechanisms of tumor resistance Helena Harlin Human Immunologic Monitoring Facility University of Chicago Introduction High frequencies of melanoma antigen-specific
More informationDrug profiling in an immune cell-tumor spheroid co-culture model
Oncology Drug Discovery Molecular Pharmacology Drug profiling in an immune cell-tumor spheroid co-culture model Silvia Goldoni, Investigator Novartis Institutes for Biomedical Research, Cambridge MA, USA
More informationBASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune
More informationACE ImmunoID. ACE ImmunoID. Precision immunogenomics. Precision Genomics for Immuno-Oncology
ACE ImmunoID ACE ImmunoID Precision immunogenomics Precision Genomics for Immuno-Oncology Personalis, Inc. A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies
More informationWelcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationInterpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment. Lorcan Sherry, CSO OracleBio
Interpreting Therapeutic Response on Immune Cell Number and Spatial Distribution within the Tumor Microenvironment Lorcan Sherry, CSO OracleBio Company Overview OracleBio is a specialised CRO providing
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationImmune Cell Phenotyping in Solid Tumors using Quantitative Pathology
Immune Cell Phenotyping in Solid Tumors using Quantitative Pathology James R. Mansfield Director of Quantitative Pathology Applications 2009 PerkinElmer What is Quantitative Pathology? Quantitative Pathology
More informationMolecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy
Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationSupplemental Materials
Supplemental Materials Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability Qi Wang 1, Jianwei He 1, Dallas B. Flies 2, Liqun Luo
More informationVenky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA
Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com
More informationSupplemental materials
Supplemental materials 1 Supplemental Fig. 1 Immunogram This immunogram summarizes patient clinical data and immune parameters at corresponding time points for Patient IMF-32. The top panel illustrates
More informationBases for Immunotherapy in Multiple Myeloma
Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationHARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER
OncoPept TM HARNESS THE POWER OF THE IMMUNE SYSTEM TO FIGHT CANCER OncoPept identifies and delivers priortized T-cell neo-epitopes from the patient's tumor mutanome 2 What is OncoPept? OncoPept is an integrated
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy in NSCLC
VENTANA (SP142) Assay Guiding immunotherapy in NSCLC Hiker s path: VENTANA (SP142) Assay on non-small cell lung cancer tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess NSCLC patient benefit
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationBiologic Basis of Immunotherapy in Lung Cancer
Biologic Basis of Immunotherapy in Lung Cancer Andrew R. Haas, MD, PhD Director, Interventional Pulmonary and Thoracic Oncology Perelman School of Medicine of the University of Pennsylvania Philadelphia,
More informationNaive, memory and regulatory T lymphocytes populations analysis
Naive, memory and regulatory T lymphocytes populations analysis Jaen Olivier, PhD ojaen@beckmancoulter.com Cellular Analysis application specialist Beckman Coulter France Introduction Flow cytometric analysis
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): This manuscript builds on the recently published observation by the same investigators that TNBC tumors with Ras/MAPK activation have decreased
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationAbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification
BD AbSeq on the BD Rhapsody system: Exploration of single-cell gene regulation by simultaneous digital mrna and protein quantification Overview of BD AbSeq antibody-oligonucleotide conjugates. High-throughput
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationDISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d
nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,
More informationSupplementary Information:
Supplementary Information: Follicular regulatory T cells with Bcl6 expression suppress germinal center reactions by Yeonseok Chung, Shinya Tanaka, Fuliang Chu, Roza Nurieva, Gustavo J. Martinez, Seema
More informationGBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS
GBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS JONATHAN BACK 1 ; MARTIN WERMKE 2 ; JULIE MACOIN 1 ; AMELIE CROSET 1 ; JOHN KAUH 3 ; VENKATESHWAR REDDY
More informationThe quest for the identification of the genetic determinants of cancer immune responsiveness
2015 Sidra Medical and Research Center The quest for the identification of the genetic determinants of cancer immune responsiveness Francesco M Marincola - Chief Research Officer Sidra Medical and Research
More informationCPM (x 10-3 ) Tregs +Teffs. Tregs alone ICOS CLTA-4
A 2,5 B 4 Number of cells (x 1-6 ) 2, 1,5 1, 5 CPM (x 1-3 ) 3 2 1 5 1 15 2 25 3 Days of culture 1/1 1/2 1/4 1/8 1/16 1/32 Treg/Teff ratio C alone alone alone alone CD25 FoxP3 GITR CD44 ICOS CLTA-4 CD127
More informationCytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression
Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?
More informationImmunology and Immunotherapy 101 for the Non-Immunologist
Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationImmunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Immunotherapeutic barriers at the level of the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and Cancer Program of the
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationCoxsackievirus A21: The basic facts
Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors An encore presentation by Jurg Rohrer, PhD, BD Biosciences 10.26.10 Outline Introduction Cytokines
More informationClinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors
Clinical Need and diagnostic challenge-the upcoming landscape of checkpointinhibitors ESP/ESMO Marina Chiara GARASSINO Amsterdam 2017 September, 4th 29 European Congress of Pathology Disclosures BMS ROCHE
More informationImmune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine
Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen
More informationUnderstanding and overcoming immunoregulatory barriers within
Understanding and overcoming immunoregulatory barriers within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader, Immunology and
More informationMECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
More informationDCVax Novel Personalized Immunotherapies for Solid Tumors
DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationNuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.
Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationNew insights into CD8+ T cell function and regulation. Pam Ohashi Princess Margaret Cancer Centre
New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre New insights into CD8+ T cell function and regulation Pam Ohashi Princess Margaret Cancer Centre No Disclosures
More informationPerspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario. Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla)
Perspectivas de desarrollo de la inmunoterapia en cáncer de mama hereditario Luis de la Cruz Merino Oncología Médica HUVMacarena (Sevilla) Outline Immunology and breast cancer Clinical trials with modern
More informationNature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.
Supplementary Figure 1 RNA-Seq analysis of CD8 + TILs and N-TILs. (a) Schematic representation of the tumor and cell types used for the study. HNSCC, head and neck squamous cell cancer; NSCLC, non-small
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationC M. Chimerigen Laboratories C M. Biologically Active BULK Proteins. Butyrophilin-like 2 [BTNL2] mil-35/fc An Inhibitory Cytokine.
www.adipogen.com 2014 fusion Proteins Laboratories The Experts for High Quality Fusion Proteins NEW NEW Butyrophilin-like 2 [BTNL2] Butyrophilin-like 2 (BTNL2) is a butyrophilin family member with homology
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationNANO 243/CENG 207 Course Use Only
L4: Nanomedicine in Immunotherapy April 12, 2018 Branches of the Immune System Body has two main branches of immunity, innate and adaptive. Innate immunity is the first line of defense. Phagocytes such
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationSUPPLEMENTAL INFORMATIONS
1 SUPPLEMENTAL INFORMATIONS Figure S1 Cumulative ZIKV production by testis explants over a 9 day-culture period. Viral titer values presented in Figure 1B (viral release over a 3 day-culture period measured
More informationVENTANA PD-L1 (SP142) Assay
VENTANA (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA (SP142) Assay Assess UC patient benefit from TECENTRIQ
More informationSupplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III
Supplementary Materials: Supplementary Figure 1. IDH1 and IDH2 mutation site sequences on WHO grade III patient samples. Genomic DNA samples extracted from punch biopsies from either FFPE or frozen tumor
More informationMolecular Profiling of Tumor Microenvironment Alex Chenchik, Ph.D. Cellecta, Inc.
Molecular Profiling of Tumor Microenvironment Alex Chenchik, Ph.D. Cellecta, Inc. Cellecta, Inc. Founded: April 2006 Headquarters: Mountain View, CA 12 SBIR Grants Custom Service Provider for Functional
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors Presented by Jurg Rohrer, PhD, BD Biosciences 23-10780-00 Outline Introduction Cytokines Transcription
More informationThe development of T cells in the thymus
T cells rearrange their receptors in the thymus whereas B cells do so in the bone marrow. The development of T cells in the thymus The lobular/cellular organization of the thymus Immature cells are called
More informationB cell activation and antibody production. Abul K. Abbas UCSF
1 B cell activation and antibody production Abul K. Abbas UCSF 2 Lecture outline B cell activation; the role of helper T cells in antibody production Therapeutic targeting of B cells 3 Principles of humoral
More informationVENTANA PD-L1 (SP142) Assay Guiding immunotherapy
VENTANA PD-L1 (SP142) Assay Guiding immunotherapy Hiker s path: VENTANA PD-L1 (SP142) Assay on urothelial carcinoma tissue Location: Point Conception, CA VENTANA PD-L1 (SP142) Assay Identify patients most
More informationExploring Therapeutic Combinations with anti-ctla-4 Antibody
Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationPD-L1 and Immunotherapy of GI cancers: What do you need to know
None. PD-L1 and Immunotherapy of GI cancers: What do you need to know Rondell P. Graham September 3, 2017 2017 MFMER slide-2 Disclosure No conflicts of interest to disclose 2017 MFMER slide-3 Objectives
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationImmune surveillance: The immune system can recognize and destroy nascent malignant cells
Immune surveillance: The immune system can recognize and destroy nascent malignant cells Control Escape APC T C T H B NKT NK Innate Tumor T cells are believed to play a major role in controlling tumor
More informationLayered-IHC (L-IHC): A novel and robust approach to multiplexed immunohistochemistry So many markers and so little tissue
Page 1 The need for multiplex detection of tissue biomarkers. There is a constant and growing demand for increased biomarker analysis in human tissue specimens. Analysis of tissue biomarkers is key to
More informationArming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)
Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More information5/1/13. The proportion of thymus that produces T cells decreases with age. The cellular organization of the thymus
T cell precursors migrate from the bone marrow via the blood to the thymus to mature 1 2 The cellular organization of the thymus The proportion of thymus that produces T cells decreases with age 3 4 1
More informationTranslating Research into Clinical Practice: Strategies Against Hepatocellular Cancer
Translating Research into Clinical Practice: Strategies Against Hepatocellular Cancer Kevin Staveley-O Carroll, PhD, MD, FACS Professor and Chair, Department of Surgery Director of the Ellis Fischel Cancer
More informationBasic mechanisms of Immunotherapy
Basic mechanisms of Immunotherapy Making it in a simple Lenguage Dr. Ada G. Blidner Ins8tute of Biology and Experimental Medicine, Buenos Aires, Argen8na adablidner@gmail.com Who, Where, When? Innate and
More informationCancer immunotherapy with oncolytic viruses: more than just lysis
Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank
More informationThe Immune Response in Time and Space
The Immune Response in Time and Space Chapters 14 & 4 Sharon S. Evans, Ph.D. Department of Immunology 845-3421 sharon.evans@roswellpark.org September 18 & 23, 2014 Inflammation Inflammation Complex response
More informationSupplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific
SUPPLEMENTARY FIGURE LEGEND Supplementary Figure 1. Enhanced detection of CTLA-4 on the surface of HIV-specific CD4 + T cells correlates with intracellular CTLA-4 levels. (a) Comparative CTLA-4 levels
More informationMarshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011
Marshall T Bell Research Resident University of Colorado Grand Rounds Nov. 21, 2011 Most common form of cancer in adults ages 25-29 3-5% of skin cancers but 65-75% of deaths Most common metastasis to small
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationHER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer
P A T H O L O G Y HER2 CISH pharmdx TM Kit Interpretation Guide Breast Cancer FROM CERTAINTY COMES TRUST For in vitro diagnostic use HER2 CISH pharmdx Kit HER2 CISH pharmdx Kit is intended for dual-color
More informationPD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs
PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium
More informationIMMUNOTARGET THERAPY: ASPETTI GENERALI
IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,
More information